[Prognostic value of molecular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations].

Breast cancer (BC) with triple-negative molecular profile is characterized by special and rather serious problems in terms of clinical management of patients compared to other types. On the one hand this is due to the fact that tumors with such a status often do not respond to routine targeted therapy and only a minimal number of drugs are currently available for their treatment. On the other hand, cases of triple-negative BC (TNBC) are often diagnosed against the background of an extensive metastatic process, in which confirmation of the metastases histogenesis to breast tissue is a difficult task due to the low sensitivity of such carcinomas to specific organ markers. It is known that about 40-50% of all TNBC cases are characterized by the achievement of complete pathomorphological regression of the primary tumor as a result of neoadjuvant chemotherapy courses, which determines a favorable prognosis of the disease. In other cases (also up to 50%), TNBC do not respond to chemotherapy and exhibit persistent drug resistance, such tumors are more aggressive, have the highest relapse rate and a high risk of metastasis. For this group of patients, the issue of finding predictive markers and new therapeutic methods remains unresolved. The presented literature review reflects the data of the analysis of publicly available results of scientific studies devoted to potentially promising molecular markers, including IDO1, DCLK1 and FOXC1, their significance in BC, including TNBC is described. Based on the analysis of literary data, it can be argued that IDO1, DCLK1 and FOXC1 are promising objects for further research in the context of TNBC. Each marker has unique characteristics that make them important both for disease prognosis and for the development of new therapeutic approaches.